UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 105

Sortiert nach

Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy

Hepatology (Baltimore, Md.), 2009-05, Vol.49 (5), p.1503-1514

2009

Volltextzugriff (PDF)

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)

Antimicrobial Agents and Chemotherapy, 2012-10, Vol.56 (10), p.5387-5396

2012

Volltextzugriff (PDF)

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion

Nature, 2005-11, Vol.438 (7064), p.99-102

2005

Volltextzugriff (PDF)

Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present

Antimicrobial Agents and Chemotherapy, 2007-03, Vol.51 (3), p.902-911

2007

Volltextzugriff (PDF)

A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients

Gastroenterology (New York, N.Y. 1943), 2005-10, Vol.129 (4), p.1198-1209

2005

Volltextzugriff (PDF)

Inhibition of Hepatitis B Virus Polymerase by Entecavir

Journal of Virology, 2007-04, Vol.81 (8), p.3992-4001

2007

Volltextzugriff (PDF)

Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir

PloS one, 2010-02, Vol.5 (2), p.e9195

2010

Volltextzugriff (PDF)

Entecavir for Treatment of Hepatitis B Virus Displays No In Vitro Mitochondrial Toxicity or DNA Polymerase Gamma Inhibition

Antimicrobial Agents and Chemotherapy, 2008-02, Vol.52 (2), p.598-605

2008

Volltextzugriff (PDF)

Activities of Atazanavir (BMS-232632) against a Large Panel of Human Immunodeficiency Virus Type 1 Clinical Isolates Resistant to One or More Approved Protease Inhibitors

Antimicrobial Agents and Chemotherapy, 2003-04, Vol.47 (4), p.1324-1333

2003

Volltextzugriff (PDF)

Long-Term Entecavir Treatment Results in Sustained Antiviral Efficacy and Prolonged Life Span in the Woodchuck Model of Chronic Hepatitis Infection

The Journal of infectious diseases, 2001-11, Vol.184 (10), p.1236-1245

2001

Volltextzugriff (PDF)

Biochemical and Genetic Characterizations of a Novel Human Immunodeficiency Virus Type 1 Inhibitor That Blocks gp120-CD4 Interactions

Journal of Virology, 2003-10, Vol.77 (19), p.10528-10536

2003

Volltextzugriff (PDF)

Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response

Journal of hepatology, 2008-06, Vol.48 (6), p.895-902

2008

Volltextzugriff (PDF)

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

Nature (London), 2010-05, Vol.465 (7294), p.96-100

2010

Volltextzugriff (PDF)

In Vitro Inhibition of Hepadnavirus Polymerases by the Triphosphates of BMS-200475 and Lobucavir

Antimicrobial Agents and Chemotherapy, 1998-12, Vol.42 (12), p.3200-3208

1998

Volltextzugriff (PDF)

BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents

Antimicrobial Agents and Chemotherapy, 2000-08, Vol.44 (8), p.2093-2099

2000

Volltextzugriff (PDF)

Inhibitors of HIV-1 attachment. Part 2: An initial survey of indole substitution patterns

Bioorganic & medicinal chemistry letters, 2009-04, Vol.19 (7), p.1977-1981

2009

Volltextzugriff (PDF)

Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir

Journal of medicinal chemistry, 2018-07, Vol.61 (14), p.6308-6327

2018

Volltextzugriff (PDF)

In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632

Antimicrobial Agents and Chemotherapy, 2000-09, Vol.44 (9), p.2319-2326

2000

Volltextzugriff (PDF)

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

Hepatology (Baltimore, Md.), 2006-12, Vol.44 (6), p.1656-1665

2006

Volltextzugriff (PDF)

Molecular Basis for Increased Susceptibility of Isolates with Atazanavir Resistance-Conferring Substitution I50L to Other Protease Inhibitors

Antimicrobial Agents and Chemotherapy, 2005-09, Vol.49 (9), p.3825-3832

2005

Volltextzugriff (PDF)

Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection

Journal of medicinal chemistry, 2014-03, Vol.57 (5), p.1708-1729

2014

Volltextzugriff (PDF)

Potent Efficacy of Entecavir (BMS-200475) in a Duck Model of Hepatitis B Virus Replication

Antimicrobial Agents and Chemotherapy, 2002-01, Vol.46 (1), p.82-88

2002

Volltextzugriff (PDF)

Metabolic Studies on BMS-200475, a New Antiviral Compound Active against Hepatitis B Virus

Antimicrobial Agents and Chemotherapy, 1999-01, Vol.43 (1), p.190-193

1999

Volltextzugriff (PDF)

Ultrasensitive Genotypic Detection of Antiviral Resistance in Hepatitis B Virus Clinical Isolates

Antimicrobial Agents and Chemotherapy, 2009-07, Vol.53 (7), p.2762-2772

2009

Volltextzugriff (PDF)

Effect of Antiviral Treatment with Entecavir on Age- and Dose-Related Outcomes of Duck Hepatitis B Virus Infection

Journal of Virology, 2005-05, Vol.79 (9), p.5819-5832

2005

Volltextzugriff (PDF)

1 – 25 von 105

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(102)
Mit Volltextzugriff
(100)

Publikationsform

Artikel
(102)
Buchkapitel
(3)

Sprache

Englisch
(105)
Japanisch
(35)

Erscheinungsjahr

n.n

Thema

Science & Technology
(87)
Life Sciences & Biomedicine
(78)
Humans
(60)
Biological And Medical Sciences
(56)
Medical Sciences
(38)
Animals
(37)
Microbiology
(37)
Pharmacology & Pharmacy
(37)
Antiviral Agents
(32)
Pharmacology. Drug Treatments
(32)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(31)
Virology
(31)
Molecular Sequence Data
(25)
Fundamental And Applied Biological Sciences. Psychology
(23)
Antiviral Agents - Pharmacology
(21)
Hiv-1 - Drug Effects
(20)
Amino Acid Sequence
(19)
Cell Line
(19)
Guanine - Analogs & Derivatives
(18)
Infectious Diseases
(18)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion

Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present

A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients

Inhibition of Hepatitis B Virus Polymerase by Entecavir

Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir

Entecavir for Treatment of Hepatitis B Virus Displays No In Vitro Mitochondrial Toxicity or DNA Polymerase Gamma Inhibition

Activities of Atazanavir (BMS-232632) against a Large Panel of Human Immunodeficiency Virus Type 1 Clinical Isolates Resistant to One or More Approved Protease Inhibitors

Long-Term Entecavir Treatment Results in Sustained Antiviral Efficacy and Prolonged Life Span in the Woodchuck Model of Chronic Hepatitis Infection

Biochemical and Genetic Characterizations of a Novel Human Immunodeficiency Virus Type 1 Inhibitor That Blocks gp120-CD4 Interactions

Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

In Vitro Inhibition of Hepadnavirus Polymerases by the Triphosphates of BMS-200475 and Lobucavir

BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents

Inhibitors of HIV-1 attachment. Part 2: An initial survey of indole substitution patterns

Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir

In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

Molecular Basis for Increased Susceptibility of Isolates with Atazanavir Resistance-Conferring Substitution I50L to Other Protease Inhibitors

Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection

Potent Efficacy of Entecavir (BMS-200475) in a Duck Model of Hepatitis B Virus Replication

Metabolic Studies on BMS-200475, a New Antiviral Compound Active against Hepatitis B Virus

Ultrasensitive Genotypic Detection of Antiviral Resistance in Hepatitis B Virus Clinical Isolates

Effect of Antiviral Treatment with Entecavir on Age- and Dose-Related Outcomes of Duck Hepatitis B Virus Infection

Suchergebnisse filtern